Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis

Magnetic resonance imaging (MRI) provides a powerful tool for assessing disease activity in multiple sclerosis (MS), and its role as a surrogate marker for monitoring treatment efficacy is now becoming established. The most commonly used MRI parameters in treatment trials are (1) monthly gadolinium‐...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of neurology 1998-03, Vol.43 (3), p.332-339
Hauptverfasser: Molyneux, P. D., Filippi, M., Barkhof, F., Gasperini, C., Yousry, T., Lruyen, L., Lai, H. M., Rocca, M. A., Moseley, I. F., Miller, D. H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 339
container_issue 3
container_start_page 332
container_title Annals of neurology
container_volume 43
creator Molyneux, P. D.
Filippi, M.
Barkhof, F.
Gasperini, C.
Yousry, T.
Lruyen, L.
Lai, H. M.
Rocca, M. A.
Moseley, I. F.
Miller, D. H.
description Magnetic resonance imaging (MRI) provides a powerful tool for assessing disease activity in multiple sclerosis (MS), and its role as a surrogate marker for monitoring treatment efficacy is now becoming established. The most commonly used MRI parameters in treatment trials are (1) monthly gadolinium‐enhanced MRI, with the number of active lesions serving as the outcome measure, and (2) annual lesion load quantification, in which change in MS lesion volume provides the MRI endpoint. We evaluated clinical/MRI correlations and the relationship between these two markers of disease activity in 73 patients with clinically definite MS. Quantification of T2 lesion load was performed at study entry and exit, with a median study duration of 11 months (range, 9 to 14 months). Monthly postgadolinium T1‐weighted images were acquired between these time points. Lesion load at study entry was significantly correlated with the baseline Expanded Disability Status Scale (EDSS) score, but no significant longitudinal correlation was demonstrated. The number of enhancing lesions on the entry scan was predictive of subsequent relapse rate over the study duration and also correlated with the subsequent enhancing lesion activity over the study period. A significant correlation was found between change in lesion load and disease activity on the monthly scans. Our results suggest that annual lesion load quantification provides an efficient measure of ongoing disease activity, and this supports its application as a surrogate marker of disease evolution in phase III treatment trials.
doi_str_mv 10.1002/ana.410430311
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79731760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79731760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4031-b04aee5ee9457ca8728b93e553a08582fac9b9c20b4dd4177fdd0f7cb55f33603</originalsourceid><addsrcrecordid>eNp9kE1v1DAURS0EKtPCkiWSF4hdyvNXnCxHEbRFQ5GqIlA3luO8UFMnmdoJZf49KRNGrFhZ8j1-vu8Q8orBKQPg72xvTyUDKUAw9oSsmBIsK7gsn5IViFxmign5nByn9AMAypzBETkqFeRKwYrcVUOMGOzohz7RGscHxJ52Qz_ehh3F_tb2Dhv66eqCbjDNEI12RGr7hro5-46J-p5e87_pzyFMHT7edVMY_TYgTS5gHJJPL8iz1oaEL5fzhHz58P66Os82n88uqvUmc3LeIatBWkSFWEqlnS00L-pSoFLCQqEK3lpX1qXjUMumkUzrtmmg1a5WqhUiB3FC3u7nbuNwP2EaTeeTwxBsj8OUjC61YPoPmO1BN_dLEVuzjb6zcWcYmEe5ZpZrDnJn_vUyeKo7bA70YnPO3yy5Tc6GNs7yfDpgnIPgMp8xvccefMDd__8068v1vwWWwj6N-Ovw0sY7k2uhlfl6eWY2Nx8r_q26MVfiNxCroZ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79731760</pqid></control><display><type>article</type><title>Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Molyneux, P. D. ; Filippi, M. ; Barkhof, F. ; Gasperini, C. ; Yousry, T. ; Lruyen, L. ; Lai, H. M. ; Rocca, M. A. ; Moseley, I. F. ; Miller, D. H.</creator><creatorcontrib>Molyneux, P. D. ; Filippi, M. ; Barkhof, F. ; Gasperini, C. ; Yousry, T. ; Lruyen, L. ; Lai, H. M. ; Rocca, M. A. ; Moseley, I. F. ; Miller, D. H.</creatorcontrib><description>Magnetic resonance imaging (MRI) provides a powerful tool for assessing disease activity in multiple sclerosis (MS), and its role as a surrogate marker for monitoring treatment efficacy is now becoming established. The most commonly used MRI parameters in treatment trials are (1) monthly gadolinium‐enhanced MRI, with the number of active lesions serving as the outcome measure, and (2) annual lesion load quantification, in which change in MS lesion volume provides the MRI endpoint. We evaluated clinical/MRI correlations and the relationship between these two markers of disease activity in 73 patients with clinically definite MS. Quantification of T2 lesion load was performed at study entry and exit, with a median study duration of 11 months (range, 9 to 14 months). Monthly postgadolinium T1‐weighted images were acquired between these time points. Lesion load at study entry was significantly correlated with the baseline Expanded Disability Status Scale (EDSS) score, but no significant longitudinal correlation was demonstrated. The number of enhancing lesions on the entry scan was predictive of subsequent relapse rate over the study duration and also correlated with the subsequent enhancing lesion activity over the study period. A significant correlation was found between change in lesion load and disease activity on the monthly scans. Our results suggest that annual lesion load quantification provides an efficient measure of ongoing disease activity, and this supports its application as a surrogate marker of disease evolution in phase III treatment trials.</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.410430311</identifier><identifier>PMID: 9506550</identifier><identifier>CODEN: ANNED3</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; Adult ; Biological and medical sciences ; Brain - pathology ; Cohort Studies ; Disability Evaluation ; Female ; Gadolinium ; Humans ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - physiopathology ; Nervous system involvement in other diseases. Miscellaneous ; Neurology ; Recurrence ; Time Factors</subject><ispartof>Annals of neurology, 1998-03, Vol.43 (3), p.332-339</ispartof><rights>Copyright © 1998 American Neurological Association</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4031-b04aee5ee9457ca8728b93e553a08582fac9b9c20b4dd4177fdd0f7cb55f33603</citedby><cites>FETCH-LOGICAL-c4031-b04aee5ee9457ca8728b93e553a08582fac9b9c20b4dd4177fdd0f7cb55f33603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.410430311$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.410430311$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2203246$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9506550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Molyneux, P. D.</creatorcontrib><creatorcontrib>Filippi, M.</creatorcontrib><creatorcontrib>Barkhof, F.</creatorcontrib><creatorcontrib>Gasperini, C.</creatorcontrib><creatorcontrib>Yousry, T.</creatorcontrib><creatorcontrib>Lruyen, L.</creatorcontrib><creatorcontrib>Lai, H. M.</creatorcontrib><creatorcontrib>Rocca, M. A.</creatorcontrib><creatorcontrib>Moseley, I. F.</creatorcontrib><creatorcontrib>Miller, D. H.</creatorcontrib><title>Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>Magnetic resonance imaging (MRI) provides a powerful tool for assessing disease activity in multiple sclerosis (MS), and its role as a surrogate marker for monitoring treatment efficacy is now becoming established. The most commonly used MRI parameters in treatment trials are (1) monthly gadolinium‐enhanced MRI, with the number of active lesions serving as the outcome measure, and (2) annual lesion load quantification, in which change in MS lesion volume provides the MRI endpoint. We evaluated clinical/MRI correlations and the relationship between these two markers of disease activity in 73 patients with clinically definite MS. Quantification of T2 lesion load was performed at study entry and exit, with a median study duration of 11 months (range, 9 to 14 months). Monthly postgadolinium T1‐weighted images were acquired between these time points. Lesion load at study entry was significantly correlated with the baseline Expanded Disability Status Scale (EDSS) score, but no significant longitudinal correlation was demonstrated. The number of enhancing lesions on the entry scan was predictive of subsequent relapse rate over the study duration and also correlated with the subsequent enhancing lesion activity over the study period. A significant correlation was found between change in lesion load and disease activity on the monthly scans. Our results suggest that annual lesion load quantification provides an efficient measure of ongoing disease activity, and this supports its application as a surrogate marker of disease evolution in phase III treatment trials.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Brain - pathology</subject><subject>Cohort Studies</subject><subject>Disability Evaluation</subject><subject>Female</subject><subject>Gadolinium</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - physiopathology</subject><subject>Nervous system involvement in other diseases. Miscellaneous</subject><subject>Neurology</subject><subject>Recurrence</subject><subject>Time Factors</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAURS0EKtPCkiWSF4hdyvNXnCxHEbRFQ5GqIlA3luO8UFMnmdoJZf49KRNGrFhZ8j1-vu8Q8orBKQPg72xvTyUDKUAw9oSsmBIsK7gsn5IViFxmign5nByn9AMAypzBETkqFeRKwYrcVUOMGOzohz7RGscHxJ52Qz_ehh3F_tb2Dhv66eqCbjDNEI12RGr7hro5-46J-p5e87_pzyFMHT7edVMY_TYgTS5gHJJPL8iz1oaEL5fzhHz58P66Os82n88uqvUmc3LeIatBWkSFWEqlnS00L-pSoFLCQqEK3lpX1qXjUMumkUzrtmmg1a5WqhUiB3FC3u7nbuNwP2EaTeeTwxBsj8OUjC61YPoPmO1BN_dLEVuzjb6zcWcYmEe5ZpZrDnJn_vUyeKo7bA70YnPO3yy5Tc6GNs7yfDpgnIPgMp8xvccefMDd__8068v1vwWWwj6N-Ovw0sY7k2uhlfl6eWY2Nx8r_q26MVfiNxCroZ4</recordid><startdate>199803</startdate><enddate>199803</enddate><creator>Molyneux, P. D.</creator><creator>Filippi, M.</creator><creator>Barkhof, F.</creator><creator>Gasperini, C.</creator><creator>Yousry, T.</creator><creator>Lruyen, L.</creator><creator>Lai, H. M.</creator><creator>Rocca, M. A.</creator><creator>Moseley, I. F.</creator><creator>Miller, D. H.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Willey-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199803</creationdate><title>Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis</title><author>Molyneux, P. D. ; Filippi, M. ; Barkhof, F. ; Gasperini, C. ; Yousry, T. ; Lruyen, L. ; Lai, H. M. ; Rocca, M. A. ; Moseley, I. F. ; Miller, D. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4031-b04aee5ee9457ca8728b93e553a08582fac9b9c20b4dd4177fdd0f7cb55f33603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Brain - pathology</topic><topic>Cohort Studies</topic><topic>Disability Evaluation</topic><topic>Female</topic><topic>Gadolinium</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - physiopathology</topic><topic>Nervous system involvement in other diseases. Miscellaneous</topic><topic>Neurology</topic><topic>Recurrence</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Molyneux, P. D.</creatorcontrib><creatorcontrib>Filippi, M.</creatorcontrib><creatorcontrib>Barkhof, F.</creatorcontrib><creatorcontrib>Gasperini, C.</creatorcontrib><creatorcontrib>Yousry, T.</creatorcontrib><creatorcontrib>Lruyen, L.</creatorcontrib><creatorcontrib>Lai, H. M.</creatorcontrib><creatorcontrib>Rocca, M. A.</creatorcontrib><creatorcontrib>Moseley, I. F.</creatorcontrib><creatorcontrib>Miller, D. H.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Molyneux, P. D.</au><au>Filippi, M.</au><au>Barkhof, F.</au><au>Gasperini, C.</au><au>Yousry, T.</au><au>Lruyen, L.</au><au>Lai, H. M.</au><au>Rocca, M. A.</au><au>Moseley, I. F.</au><au>Miller, D. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>1998-03</date><risdate>1998</risdate><volume>43</volume><issue>3</issue><spage>332</spage><epage>339</epage><pages>332-339</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><coden>ANNED3</coden><abstract>Magnetic resonance imaging (MRI) provides a powerful tool for assessing disease activity in multiple sclerosis (MS), and its role as a surrogate marker for monitoring treatment efficacy is now becoming established. The most commonly used MRI parameters in treatment trials are (1) monthly gadolinium‐enhanced MRI, with the number of active lesions serving as the outcome measure, and (2) annual lesion load quantification, in which change in MS lesion volume provides the MRI endpoint. We evaluated clinical/MRI correlations and the relationship between these two markers of disease activity in 73 patients with clinically definite MS. Quantification of T2 lesion load was performed at study entry and exit, with a median study duration of 11 months (range, 9 to 14 months). Monthly postgadolinium T1‐weighted images were acquired between these time points. Lesion load at study entry was significantly correlated with the baseline Expanded Disability Status Scale (EDSS) score, but no significant longitudinal correlation was demonstrated. The number of enhancing lesions on the entry scan was predictive of subsequent relapse rate over the study duration and also correlated with the subsequent enhancing lesion activity over the study period. A significant correlation was found between change in lesion load and disease activity on the monthly scans. Our results suggest that annual lesion load quantification provides an efficient measure of ongoing disease activity, and this supports its application as a surrogate marker of disease evolution in phase III treatment trials.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>9506550</pmid><doi>10.1002/ana.410430311</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0364-5134
ispartof Annals of neurology, 1998-03, Vol.43 (3), p.332-339
issn 0364-5134
1531-8249
language eng
recordid cdi_proquest_miscellaneous_79731760
source MEDLINE; Access via Wiley Online Library
subjects Adolescent
Adult
Biological and medical sciences
Brain - pathology
Cohort Studies
Disability Evaluation
Female
Gadolinium
Humans
Magnetic Resonance Imaging
Male
Medical sciences
Middle Aged
Multiple Sclerosis - diagnosis
Multiple Sclerosis - physiopathology
Nervous system involvement in other diseases. Miscellaneous
Neurology
Recurrence
Time Factors
title Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-10T19%3A35%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlations%20between%20monthly%20enhanced%20MRI%20Lesion%20rate%20and%20changes%20in%20T2%20Lesion%20volume%20in%20multiple%20sclerosis&rft.jtitle=Annals%20of%20neurology&rft.au=Molyneux,%20P.%20D.&rft.date=1998-03&rft.volume=43&rft.issue=3&rft.spage=332&rft.epage=339&rft.pages=332-339&rft.issn=0364-5134&rft.eissn=1531-8249&rft.coden=ANNED3&rft_id=info:doi/10.1002/ana.410430311&rft_dat=%3Cproquest_cross%3E79731760%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79731760&rft_id=info:pmid/9506550&rfr_iscdi=true